PubMed:8608243
Annnotations
DisGeNET
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T0 | 761-798 | gene:1440 | denotes | granulocyte colony-stimulating factor |
| T1 | 704-707 | disease:C0023487 | denotes | APL |
| T2 | 800-805 | gene:1440 | denotes | G-CSF |
| T3 | 704-707 | disease:C0023487 | denotes | APL |
| R1 | T0 | T1 | associated_with | granulocyte colony-stimulating factor,APL |
| R2 | T2 | T3 | associated_with | G-CSF,APL |
jnlpba-st-training
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 112-146 | cell_line | denotes | acute promyelocytic leukemia cells |
| T2 | 292-301 | cell_line | denotes | APL cells |
| T3 | 310-317 | protein | denotes | PML-RAR |
| T4 | 343-376 | protein | denotes | retinoic acid receptor type alpha |
| T5 | 378-387 | protein | denotes | RAR alpha |
| T6 | 406-458 | DNA | denotes | leukemia-specific t(15;17) chromosomal translocation |
| T7 | 547-556 | protein | denotes | RAR alpha |
| T8 | 618-621 | cell_line | denotes | NB4 |
| T9 | 626-647 | cell_line | denotes | APL-derived cell line |
| T10 | 656-683 | cell_type | denotes | freshly isolated APL blasts |
| T11 | 704-713 | cell_line | denotes | APL cells |
| T12 | 761-798 | protein | denotes | granulocyte colony-stimulating factor |
| T13 | 800-805 | protein | denotes | G-CSF |
| T14 | 900-968 | RNA | denotes | leukocyte alkaline phosphatase, CD11b, CD33, and G-CSF receptor mRNA |
| T15 | 1158-1181 | protein | denotes | differentiation markers |
| T16 | 1189-1204 | cell_line | denotes | HL-60 cell line |
| T17 | 1212-1241 | cell_type | denotes | freshly isolated granulocytes |
| T18 | 1361-1370 | cell_line | denotes | NB4 cells |
| T19 | 1441-1444 | protein | denotes | LAP |
| T20 | 1673-1680 | protein | denotes | PML-RAR |
| T21 | 1720-1731 | cell_line | denotes | COS-7 cells |
| T22 | 1761-1768 | protein | denotes | PML-RAR |
| T23 | 1784-1793 | protein | denotes | RAR alpha |
| T24 | 1890-1897 | protein | denotes | PML-RAR |
| T25 | 1957-2010 | DNA | denotes | retinoic acid-responsive element-containing promoters |
| T26 | 2066-2075 | protein | denotes | RAR alpha |
| T27 | 2186-2219 | cell_type | denotes | PML-RAR-containing leukemic cells |
DisGeNET5_gene_disease
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 8608243-2#33#40#gene84106 | 310-317 | gene84106 | denotes | PML-RAR |
| 8608243-2#129#137#diseaseC0023418 | 406-414 | diseaseC0023418 | denotes | leukemia |
| 8608243-4#76#113#gene1440 | 761-798 | gene1440 | denotes | granulocyte colony-stimulating factor |
| 8608243-4#19#22#diseaseC0023487 | 704-707 | diseaseC0023487 | denotes | APL |
| 33#40#gene84106129#137#diseaseC0023418 | 8608243-2#33#40#gene84106 | 8608243-2#129#137#diseaseC0023418 | associated_with | PML-RAR,leukemia |
| 76#113#gene144019#22#diseaseC0023487 | 8608243-4#76#113#gene1440 | 8608243-4#19#22#diseaseC0023487 | associated_with | granulocyte colony-stimulating factor,APL |
pubmed-sentences-benchmark
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| S1 | 0-147 | Sentence | denotes | AM580, a stable benzoic derivative of retinoic acid, has powerful and selective cyto-differentiating effects on acute promyelocytic leukemia cells. |
| S2 | 148-276 | Sentence | denotes | All-trans retinoic acid (ATRA) is successfully used in the cyto-differentiating treatment of acute promyelocytic leukemia (APL). |
| S3 | 277-459 | Sentence | denotes | Paradoxically, APL cells express PML-RAR, an aberrant form of the retinoic acid receptor type alpha (RAR alpha) derived from the leukemia-specific t(15;17) chromosomal translocation. |
| S4 | 460-684 | Sentence | denotes | We show here that AM580, a stable retinobenzoic derivative originally synthesized as a RAR alpha agonist, is a powerful inducer of granulocytic maturation in NB4, an APL-derived cell line, and in freshly isolated APL blasts. |
| S5 | 685-1075 | Sentence | denotes | After treatment of APL cells with AM580 either alone or in combination with granulocyte colony-stimulating factor (G-CSF), the compound induces granulocytic maturation, as assessed by determination of the levels of leukocyte alkaline phosphatase, CD11b, CD33, and G-CSF receptor mRNA, at concentrations that are 10- to 100-fold lower than those of ATRA necessary to produce similar effects. |
| S6 | 1076-1357 | Sentence | denotes | By contrast, AM580 is not effective as ATRA in modulating the expression of these differentiation markers in the HL-60 cell line and in freshly isolated granulocytes obtained from the peripheral blood of chronic myelogenous leukemia patients during the stable phase of the disease. |
| S7 | 1358-1535 | Sentence | denotes | In NB4 cells, two other synthetic nonselective RAR ligands are capable of inducing LAP as much as AM580, whereas RAR beta- or RAR gamma-specific ligands are totally ineffective. |
| S8 | 1536-1692 | Sentence | denotes | These results show that AM580 is more powerful than ATRA in modulating the expression of differentiation antigens only in cells in which PML-RAR is present. |
| S9 | 1693-1861 | Sentence | denotes | Binding experiments, using COS-7 cells transiently transfected with PML-RAR and the normal RAR alpha, show that AM580 has a lower affinity than ATRA for both receptors. |
| S10 | 1862-2114 | Sentence | denotes | However, in the presence of PML-RAR, the synthetic retinoid is a much better transactivator of retinoic acid-responsive element-containing promoters than the natural retinoid, whereas, in the presence of RAR alpha, AM580 and ATRA have similar activity. |
| S11 | 2115-2220 | Sentence | denotes | This may explain the strong cyto-differentiating potential of AM580 in PML-RAR-containing leukemic cells. |
genia-medco-coref
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| C1 | 0-5 | NP | denotes | AM580 |
| C2 | 7-51 | NP | denotes | a stable benzoic derivative of retinoic acid |
| C3 | 112-146 | NP | denotes | acute promyelocytic leukemia cells |
| C4 | 148-178 | NP | denotes | All-trans retinoic acid (ATRA) |
| C5 | 241-275 | NP | denotes | acute promyelocytic leukemia (APL) |
| C6 | 292-301 | NP | denotes | APL cells |
| C7 | 310-317 | NP | denotes | PML-RAR |
| C8 | 319-458 | NP | denotes | an aberrant form of the retinoic acid receptor type alpha (RAR alpha) derived from the leukemia-specific t(15;17) chromosomal translocation |
| C9 | 478-483 | NP | denotes | AM580 |
| C10 | 485-564 | NP | denotes | a stable retinobenzoic derivative originally synthesized as a RAR alpha agonist |
| C11 | 618-621 | NP | denotes | NB4 |
| C13 | 626-630 | NP | denotes | APL- |
| C12 | 623-647 | NP | denotes | an APL-derived cell line |
| C14 | 704-713 | NP | denotes | APL cells |
| C15 | 719-724 | NP | denotes | AM580 |
| C16 | 808-820 | NP | denotes | the compound |
| C17 | 973-987 | NP | denotes | concentrations |
| C18 | 988-992 | NP | denotes | that |
| C19 | 1024-1029 | NP | denotes | those |
| C20 | 1033-1037 | NP | denotes | ATRA |
| C21 | 1089-1094 | NP | denotes | AM580 |
| C22 | 1115-1119 | NP | denotes | ATRA |
| C23 | 1345-1356 | NP | denotes | the disease |
| C24 | 1361-1370 | NP | denotes | NB4 cells |
| C25 | 1456-1461 | NP | denotes | AM580 |
| C26 | 1560-1565 | NP | denotes | AM580 |
| C27 | 1588-1592 | NP | denotes | ATRA |
| C28 | 1658-1663 | NP | denotes | cells |
| C29 | 1667-1672 | NP | denotes | which |
| C30 | 1673-1680 | NP | denotes | PML-RAR |
| C31 | 1761-1768 | NP | denotes | PML-RAR |
| C32 | 1773-1793 | NP | denotes | the normal RAR alpha |
| C33 | 1805-1810 | NP | denotes | AM580 |
| C34 | 1837-1841 | NP | denotes | ATRA |
| C35 | 1846-1860 | NP | denotes | both receptors |
| C36 | 1890-1897 | NP | denotes | PML-RAR |
| C37 | 2077-2082 | NP | denotes | AM580 |
| C38 | 2087-2091 | NP | denotes | ATRA |
| C39 | 2177-2182 | NP | denotes | AM580 |
| C40 | 2186-2194 | NP | denotes | PML-RAR- |
| R1 | C2 | C1 | coref-appos | a stable benzoic derivative of retinoic acid,AM580 |
| R2 | C6 | C3 | coref-ident | APL cells,acute promyelocytic leukemia cells |
| R3 | C8 | C7 | coref-appos | an aberrant form of the retinoic acid receptor type alpha (RAR alpha) derived from the leukemia-specific t(15;17) chromosomal translocation,PML-RAR |
| R4 | C9 | C1 | coref-ident | AM580,AM580 |
| R5 | C10 | C9 | coref-appos | a stable retinobenzoic derivative originally synthesized as a RAR alpha agonist,AM580 |
| R6 | C13 | C5 | coref-ident | APL-,acute promyelocytic leukemia (APL) |
| R7 | C12 | C11 | coref-appos | an APL-derived cell line,NB4 |
| R8 | C14 | C6 | coref-ident | APL cells,APL cells |
| R9 | C15 | C9 | coref-ident | AM580,AM580 |
| R10 | C16 | C15 | coref-ident | the compound,AM580 |
| R11 | C18 | C17 | coref-relat | that,concentrations |
| R12 | C19 | C17 | coref-pron | those,concentrations |
| R13 | C20 | C4 | coref-ident | ATRA,All-trans retinoic acid (ATRA) |
| R14 | C21 | C15 | coref-ident | AM580,AM580 |
| R15 | C22 | C20 | coref-ident | ATRA,ATRA |
| R16 | C23 | C5 | coref-ident | the disease,acute promyelocytic leukemia (APL) |
| R17 | C24 | C11 | coref-ident | NB4 cells,NB4 |
| R18 | C25 | C21 | coref-ident | AM580,AM580 |
| R19 | C26 | C25 | coref-ident | AM580,AM580 |
| R20 | C27 | C22 | coref-ident | ATRA,ATRA |
| R21 | C29 | C28 | coref-relat | which,cells |
| R22 | C31 | C30 | coref-ident | PML-RAR,PML-RAR |
| R23 | C33 | C26 | coref-ident | AM580,AM580 |
| R24 | C34 | C27 | coref-ident | ATRA,ATRA |
| R25 | C35 | C30 | coref-whole-part | both receptors,PML-RAR |
| R26 | C35 | C40 | coref-whole-part | both receptors,PML-RAR- |
| R27 | C36 | C30 | coref-ident | PML-RAR,PML-RAR |
| R28 | C37 | C33 | coref-ident | AM580,AM580 |
| R29 | C38 | C27 | coref-ident | ATRA,ATRA |
| R30 | C39 | C37 | coref-ident | AM580,AM580 |
| R31 | C40 | C36 | coref-ident | PML-RAR-,PML-RAR |
GENIAcorpus
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-5 | other_organic_compound | denotes | AM580 |
| T2 | 16-34 | other_organic_compound | denotes | benzoic derivative |
| T3 | 38-51 | other_organic_compound | denotes | retinoic acid |
| T4 | 80-108 | other_name | denotes | cyto-differentiating effects |
| T5 | 112-146 | cell_line | denotes | acute promyelocytic leukemia cells |
| T6 | 148-171 | other_organic_compound | denotes | All-trans retinoic acid |
| T7 | 173-177 | other_organic_compound | denotes | ATRA |
| T8 | 207-237 | other_name | denotes | cyto-differentiating treatment |
| T9 | 241-269 | other_name | denotes | acute promyelocytic leukemia |
| T10 | 271-274 | other_name | denotes | APL |
| T11 | 292-301 | cell_line | denotes | APL cells |
| T12 | 310-317 | protein_molecule | denotes | PML-RAR |
| T13 | 343-356 | other_organic_compound | denotes | retinoic acid |
| T14 | 378-387 | protein_molecule | denotes | RAR alpha |
| T15 | 406-458 | DNA_domain_or_region | denotes | leukemia-specific t(15;17) chromosomal translocation |
| T16 | 478-483 | other_organic_compound | denotes | AM580 |
| T17 | 494-518 | other_organic_compound | denotes | retinobenzoic derivative |
| T18 | 547-556 | protein_molecule | denotes | RAR alpha |
| T19 | 591-614 | other_name | denotes | granulocytic maturation |
| T20 | 618-621 | cell_line | denotes | NB4 |
| T21 | 626-629 | other_name | denotes | APL |
| T22 | 656-683 | cell_type | denotes | freshly isolated APL blasts |
| T23 | 704-713 | cell_line | denotes | APL cells |
| T24 | 719-724 | other_organic_compound | denotes | AM580 |
| T25 | 761-798 | protein_molecule | denotes | granulocyte colony-stimulating factor |
| T26 | 800-805 | protein_molecule | denotes | G-CSF |
| T27 | 829-852 | other_name | denotes | granulocytic maturation |
| T28 | 1033-1037 | other_organic_compound | denotes | ATRA |
| T29 | 1089-1094 | other_organic_compound | denotes | AM580 |
| T30 | 1115-1119 | other_organic_compound | denotes | ATRA |
| T31 | 1158-1181 | protein_family_or_group | denotes | differentiation markers |
| T32 | 1189-1204 | cell_line | denotes | HL-60 cell line |
| T33 | 1212-1241 | cell_type | denotes | freshly isolated granulocytes |
| T34 | 1260-1276 | tissue | denotes | peripheral blood |
| T35 | 1280-1317 | multi_cell | denotes | chronic myelogenous leukemia patients |
| T36 | 1361-1370 | cell_line | denotes | NB4 cells |
| T37 | 1382-1416 | other_organic_compound | denotes | synthetic nonselective RAR ligands |
| T38 | 1441-1444 | protein_molecule | denotes | LAP |
| T39 | 1456-1461 | other_organic_compound | denotes | AM580 |
| T40 | 1471-1480 | other_organic_compound | denotes | RAR beta- |
| T41 | 1484-1510 | other_organic_compound | denotes | RAR gamma-specific ligands |
| T42 | 1560-1565 | other_organic_compound | denotes | AM580 |
| T43 | 1588-1592 | other_organic_compound | denotes | ATRA |
| T44 | 1673-1680 | protein_molecule | denotes | PML-RAR |
| T45 | 1720-1731 | cell_line | denotes | COS-7 cells |
| T46 | 1761-1768 | protein_molecule | denotes | PML-RAR |
| T47 | 1784-1793 | protein_molecule | denotes | RAR alpha |
| T48 | 1805-1810 | other_organic_compound | denotes | AM580 |
| T49 | 1837-1841 | other_organic_compound | denotes | ATRA |
| T50 | 1890-1897 | protein_molecule | denotes | PML-RAR |
| T51 | 1903-1921 | other_organic_compound | denotes | synthetic retinoid |
| T52 | 1957-1970 | other_organic_compound | denotes | retinoic acid |
| T53 | 2020-2036 | other_organic_compound | denotes | natural retinoid |
| T54 | 2066-2075 | protein_molecule | denotes | RAR alpha |
| T55 | 2077-2082 | other_organic_compound | denotes | AM580 |
| T56 | 2087-2091 | other_organic_compound | denotes | ATRA |
| T57 | 2143-2173 | other_name | denotes | cyto-differentiating potential |
| T58 | 2177-2182 | other_organic_compound | denotes | AM580 |
| T59 | 2186-2193 | protein_molecule | denotes | PML-RAR |